All In Biotech

Drug Trial Radar · NCT00518089

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

Last checked: Nov 20, 2026Latest source record: Apr 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 859 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

859

Actual

Start

Feb 2008

Primary completion

Jan 2009

Study completion Jan 2009

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 20, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis

Conditions

  • Bacterial Conjunctivitis

Interventions

  • Gatifloxacin 0.5% eye dropsDrug

    Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily

  • placebo eye dropsDrug

    Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6Time frame: 6 Days

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Downey, California

  • Site not named

    RajajiNagar, Bangalore, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.